Stein Steven, DeMichele Angie, Domchek Susan, Fox Kevin
Abramson Cancer Center, University of Pennsylvania, Philadelphia 19104, USA.
Clin Breast Cancer. 2004 Jan;4 Suppl 3:S117-20. doi: 10.3816/cbc.2004.s.005.
In HER2/neu-positive metastatic breast cancer, the combination of chemotherapy and trastuzumab has become a standard of care. This review discusses HER2/neu overexpression in breast cancer and the use of trastuzumab-based therapies. Specifically, the rationale for a gemcitabine/trastuzumab combination in this disease entity and the available clinical data on the use of the combination are discussed. Response rates of 12%-42% have been seen with single-agent gemcitabine and 37%-62% with trastuzumab/gemcitabine combinations. Further work is currently ongoing to examine this promising combination.
在人表皮生长因子受体2（HER2/neu）阳性转移性乳腺癌中，化疗与曲妥珠单抗联合已成为标准治疗方案。本综述讨论了乳腺癌中HER2/neu的过表达以及基于曲妥珠单抗的治疗方法的应用。具体而言，探讨了吉西他滨/曲妥珠单抗联合用于该疾病实体的理论依据以及该联合用药的现有临床数据。单药吉西他滨的缓解率为12% - 42%，曲妥珠单抗/吉西他滨联合用药的缓解率为37% - 62%。目前正在进行进一步的研究以检验这种前景广阔的联合用药方案。
